Balcinrenone
Balcinrenone is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | Balcinrenone |
| INN | balcinrenone |
| Description | Balcinrenone is an experimental selective mineralocorticoid receptor modulator developed by AstraZeneca for heart failure. Compared to mineralocorticoid receptor antagonists, it is hoped to have less effect on electrolytes and therefore a lower risk of hyperkalemia.
|
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2 |
Identifiers
| PDB | — |
| CAS-ID | 1850385-64-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3916929 |
| ChEBI ID | — |
| PubChem CID | 118599727 |
| DrugBank | — |
| UNII ID | 6C9UKZ0CYE (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use